Kabootari Maryam, Tamehri Zadeh Seyed Saeed, Hasheminia Mitra, Azizi Fereidoun, Hadaegh Farzad
Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Front Cardiovasc Med. 2023 Jun 9;10:1044638. doi: 10.3389/fcvm.2023.1044638. eCollection 2023.
Hypertension (HTN) is known to be the leading cause of cardiovascular disease (CVD) and mortality. We aimed to assess the impact of changes in 3 years in different blood pressure (BP) categories on incident CVD.
In this study, 3,685 Tehranians aged ≥30 years (42.2% men) free of prevalent CVD with BP level <140/90 mmHg and not on BP-lowering medications were enrolled. Participants were grouped according to baseline BP category using the 2017 ACC/AHA hypertension guideline definition: normal BP (<120/80 mmHg), elevated BP (120-129/<80), and stage 1 HTN (130-139 and/or 80-89). The hazard ratio of incident CVD by changes in the BP category was estimated after adjustment for traditional risk factors using Cox's proportional hazard model, with stable normotension as a reference.
During a median follow-up of 11.7 years, 346 CVD events (men = 208) occurred. Compared to the reference group, among participants with normal BP at baseline, only those with BP rising to stage 1 HTN [1.47 (0.99-2.16)], and among those with stage 1 HTN at baseline, regression to elevated BP [1.80 (1.11-2.91)], remaining at stage 1 [1.80 (1.29-2.52)], and progression to stage 2 HTN [1.81 (1.25-2.61)] had a higher risk for CVD; however, regression to normal BP attenuated this risk [1.36 (0.88-2.12)]. Conversion from elevated BP to any other categories had no significant association with CVD risk.
Generally, prevalent stage 1 HTN (regardless of changing category) and incident stage 1 HTN were significantly associated with a higher risk of CVD; even regression to elevated BP did not attenuate the risk. Accordingly, these populations are potential candidates for antihypertensive management.
高血压(HTN)是已知的心血管疾病(CVD)和死亡的主要原因。我们旨在评估3年内不同血压(BP)类别变化对CVD发病的影响。
在本研究中,纳入了3685名年龄≥30岁(男性占42.2%)、无CVD病史、血压水平<140/90 mmHg且未服用降压药物的德黑兰人。根据2017年美国心脏病学会/美国心脏协会高血压指南定义,参与者按基线BP类别分组:正常血压(<120/80 mmHg)、血压升高(120 - 129/<80)和1期高血压(130 - 139和/或80 - 89)。使用Cox比例风险模型在对传统危险因素进行调整后,以稳定的正常血压为参照,估计BP类别变化导致的CVD发病风险比。
在中位随访11.7年期间,发生了346例CVD事件(男性 = 208例)。与参照组相比,基线时血压正常的参与者中,只有血压升至1期高血压的参与者[1.47(0.99 - 2.16)],以及基线时为1期高血压的参与者中,血压回归至血压升高[1.80(1.11 - 2.91)]、维持在1期[1.80(1.29 - 2.52)]和进展至2期高血压[1.81(1.25 - 2.61)]的参与者发生CVD的风险更高;然而,血压回归至正常血压可降低这种风险[1.36(0.88 - 2.12)]。血压从升高转变为其他任何类别与CVD风险无显著关联。
一般而言,现患1期高血压(无论类别是否改变)和新发1期高血压与较高的CVD风险显著相关;即使血压回归至血压升高也未降低风险。因此,这些人群是抗高血压治疗的潜在对象。